Mahama Says U.S. Wants to Reopen Talks on Rejected Health Agreement

By: Ebenezer Adugyamfi / Emmanuel Ayiku for GhanaianNewsCanada

12 October 2026

President John Dramani Mahama has disclosed that the United States government wants to reopen discussions with Ghana over a proposed US$109 million health agreement that was rejected by Cabinet earlier this year over concerns about national sovereignty, the protection of sensitive medical information and the regulatory authority of Ghana’s Food and Drugs Authority (FDA).

The President made the disclosure during a citizens’ engagement in Goaso, the capital of the Ahafo Region, on Saturday, October 10, as part of his two-day Resetting Ghana Tour.

According to Mahama, Washington has requested further discussions on provisions Ghana considers unacceptable, with the possibility of amending or removing some of the disputed clauses.

He indicated that Ghana was prepared to engage with the United States but would maintain its position on issues involving the country’s sovereignty and the protection of its citizens’ interests.

The development could reopen negotiations over a five-year health compact intended to provide US$109 million in American assistance to Ghana’s health sector.

Ghana rejected the proposed agreement in April 2026 after reviewing its conditions. The decision followed concerns that certain provisions could give the United States access to sensitive health information and limit the ability of Ghanaian authorities to regulate medical products entering the country under the programme.

The latest disclosure signals a possible diplomatic opening between the two countries, although no date has been announced for the renewed negotiations and no revised agreement has been finalised.

Why Ghana Rejected the US$109 Million Health Compact

The proposed health compact was part of a broader United States strategy to restructure its foreign health assistance arrangements with partner countries.

The initiative seeks to establish new bilateral agreements covering areas such as HIV/AIDS, malaria, tuberculosis and other public health priorities, while encouraging recipient countries to contribute more of their own resources towards healthcare programmes.

For Ghana, the proposed agreement was expected to provide US$109 million in assistance over five years.

However, the government raised objections after reviewing the conditions attached to the proposed arrangement.

Mahama previously explained Ghana’s position during an address at the Council on Foreign Relations in New York in September.

He said the Ministry of Health had examined the draft agreement and submitted its concerns to Cabinet, which subsequently decided that Ghana should not proceed with the proposed terms.

The objections centred on the handling of sensitive health information, the country’s financial obligations and restrictions that could affect the FDA’s regulatory responsibilities.

The government maintained that international health cooperation should not require Ghana to surrender control over information relating to its citizens or weaken the authority of its national institutions.

The rejection therefore reflected a disagreement over the conditions attached to the funding rather than a declaration that Ghana was opposed to health cooperation with the United States.

Concerns Over Medical Records and Pathogen Data

One of the most significant disagreements concerned provisions relating to the sharing of Ghana’s national pathogen profiles and citizens’ medical records.

Pathogen profiles contain information about disease-causing organisms circulating within a population. Such information can help public health authorities identify outbreaks, monitor infectious diseases and prepare responses to emerging health threats.

Medical records, meanwhile, may contain highly sensitive information about individuals, including their diagnoses, treatment histories and other personal health details.

Ghana expressed concern about the scope of the information it would be required to share and whether sufficient safeguards would protect the data.

The government argued that the proposed conditions raised questions about who would have access to the information, how it could be used and what protections would apply to Ghanaian citizens.

The concerns also relate to the country’s ability to control sensitive information generated by its healthcare system.

Ghana’s Data Protection Commission has previously raised concerns about the scope of data access contemplated under the proposed arrangement.

The issue is particularly significant because health data can have implications beyond individual privacy. Information about disease prevalence, infectious organisms and public health vulnerabilities can also be important to national health planning and emergency preparedness.

For the government, any revised agreement would therefore need to address the terms under which information could be shared, the purposes for which it could be used and the safeguards governing access and storage.

The United States and Ghana may still be able to negotiate arrangements for legitimate public health cooperation, but the disputed provisions would need to be addressed before a new agreement could proceed.

Ghana Questions Restrictions on the Food and Drugs Authority

Another major concern involved the regulatory powers of Ghana’s Food and Drugs Authority.

The FDA is responsible for regulating food, medicines, medical devices and other products under its mandate to protect public health.

Ghana objected to provisions that would restrict the authority’s ability to inspect medicines and other medical products brought into the country under the proposed programme.

The government considered the issue important because product inspections and regulatory controls help ensure that medicines and medical products meet applicable safety and quality requirements.

Any restriction on the FDA’s ability to perform its duties could raise questions about the enforcement of national standards and the protection of patients.

For Ghana, accepting international health assistance should not mean surrendering the ability to determine whether medical products entering the country comply with domestic regulatory requirements.

The issue could become a central part of the renewed negotiations, particularly if the United States seeks to preserve provisions that would facilitate the delivery of medical supplies under the agreement.

A revised compact would need to clarify how the programme could operate while respecting Ghana’s laws and the FDA’s statutory responsibilities.

Financial Commitments Also Raised Questions

Beyond data protection and regulatory authority, Ghana also raised concerns about its financial obligations under the proposed agreement.

The compact included provisions requiring Ghana to provide counterpart funding, meaning the government would contribute domestic resources alongside the assistance supplied by the United States.

Such arrangements are commonly used in international development programmes to encourage recipient governments to share costs and demonstrate financial commitment to projects.

However, the terms of the proposed compact prompted questions about the size of Ghana’s contribution and the overall balance of obligations between the two countries.

The government has been seeking to strengthen its domestic capacity to finance healthcare services while managing competing demands on public resources.

Consequently, any new agreement would need to provide clarity on the financial responsibilities of both parties, how the money would be used and what results the programme would be expected to deliver.

The negotiations could therefore involve more than simply removing disputed data-sharing clauses. They may also require a review of funding arrangements, implementation responsibilities and the conditions governing the delivery of health assistance.

What the Renewed Talks Could Mean for Ghana’s Health Sector

The US$109 million compact was intended to support Ghana’s health sector over five years, making the proposed agreement significant for discussions about healthcare financing and international cooperation.

A revised agreement could potentially create a path towards renewed assistance if both governments can resolve the disagreements that led to its rejection.

However, the exact implications for Ghana’s healthcare programmes will depend on the terms eventually negotiated and whether a new agreement is signed.

It is also important to distinguish the rejected compact from other US health assistance arrangements.

The United States has previously provided funding to Ghana for public health programmes, and American diplomatic officials have said that the rejection of the proposed compact did not mean all existing or previously planned health assistance had automatically stopped.

In comments reported by Ghanaian media, the US Embassy indicated that assistance allocations for 2025 and 2026 were based on earlier planning arrangements.

The extent to which those funds remain available for specific programmes depends on their individual funding arrangements and implementation conditions.

Consequently, the proposed US$109 million compact should not be treated as the total value of all American health assistance to Ghana.

The renewed talks may help clarify what future support could be provided under a revised arrangement, but neither the final funding terms nor the outcome of the negotiations is yet known.

Ghana’s Position on National Sovereignty

Mahama’s latest comments reflect the government’s position that international development partnerships must respect Ghana’s independence and its ability to make decisions in the national interest.

The President has argued that Ghana is willing to cooperate with international partners but will not accept conditions that undermine the country’s dignity or control over its institutions.

The issue also connects with wider discussions about how African countries negotiate foreign assistance agreements.

Governments across the continent have been reviewing the terms of international health partnerships, particularly where agreements involve access to sensitive data, domestic financial commitments or the authority of national regulators.

For Ghana, the challenge is to secure external support while maintaining control over public health priorities, citizens’ information and the institutions responsible for safeguarding medical standards.

The government’s willingness to reopen discussions suggests that it sees room for a negotiated solution, provided the disputed provisions can be addressed.

Nevertheless, the willingness to negotiate does not mean Ghana has agreed to accept a revised compact. Any eventual decision will depend on the terms presented and whether they satisfy the government’s concerns.

A Wider African Debate Over US Health Assistance

Ghana’s experience is part of a wider debate over the future of American health assistance in Africa.

The administration of US President Donald Trump has pursued a new approach to foreign health funding through bilateral agreements that place greater emphasis on co-financing, accountability and recipient-country contributions.

Supporters of the approach argue that such agreements can encourage countries to assume greater responsibility for financing their own healthcare systems over time.

Critics, however, have raised concerns about provisions dealing with health data, the protection of personal information and the conditions attached to financial assistance.

Other African countries have also questioned aspects of the proposed agreements.

Zambia, for example, has pursued revisions to its own health compact, while Zimbabwe has rejected a proposed agreement amid concerns about data-sharing provisions.

Kenya’s agreement has also faced legal challenges over issues associated with access to health information.

These developments illustrate the difficult balance governments must strike between securing international funding and ensuring that the conditions attached to it are compatible with national laws and public interests.

The specific terms differ from country to country, meaning the outcome of Ghana’s negotiations will depend on its own discussions with Washington rather than on the arrangements reached elsewhere.

What Happens Next?

The immediate next step is expected to be further engagement between Ghanaian and American officials over the clauses that led to the rejection of the original agreement.

Mahama has indicated that Ghana is prepared to sit down with the United States to discuss provisions that Washington is willing to amend or remove.

However, the government has not announced a date for the discussions, and there is no confirmed timeline for a revised compact.

The outcome will depend on whether the two sides can agree on acceptable terms covering health data, regulatory authority, financial obligations and the implementation of the proposed programme.

Any new agreement would also need to pass through the relevant government review and approval processes before it could take effect.

For now, Ghana’s position remains that international health cooperation is welcome, but the country must retain the ability to protect its citizens’ medical information and exercise its regulatory responsibilities.

The renewed engagement offers an opportunity for both governments to revisit the disputed conditions. Whether that opportunity leads to a new agreement will depend on the concessions each side is prepared to make and the safeguards ultimately included in any revised arrangement.